focus -WSS

focus

author：comprehensive 2025-10-02 12:18:07 Page View：7

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made
Next article： Heart attack and stroke risk calculators need revising

explore

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Shifting the focus from loneliness to social health

AdobeIt’sbeenoneyearsincetheU.S.surgeongeneralissuedanationalwarningaboutanepidemicofloneliness.Othe

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ChrisBoshoff,farright,speakingatapanelwith,fromleft,MatthewHerperofSTAT,KenKeller,LeviGarraway,andSu